Introduction: In this study, we aimed to report the clinical outcomes of antral BTX-A injection in the absence of wide- spread injections and compare the results with the control cases who only were under a diet program without any invasive procedure. Methods: Intragastric BTX-A injection was performed in 42 patients. Meanwhile, 38 age- and gender-matched pa- tients who started a new diet program were included in the control group. Only the patients with a body mass index (BMI) between 30 kg/m2 and 35 kg/m2 were included for analysis. Results: In total, 42 patients (11 males, 31 females) who had intragastric BTX-A injection and 38 patients (8 males, 30 females) who were under a diet program were included in this study. In the group administered with BTX-A, the mini- mum weight loss in this 5-month period was 7 kg, and the maximum weight lost was 19 kg with a mean of 14.48±2.20 kg; while the minimum weight loss in this 5-month period was 5 kg and the maximum weight lost was 13 kg with a mean of 10.78±2.09 kg in the control group (p=0.001). Discussion and Conclusion: Intragastric BTX-A injection, barely to the antrum, was determined to be more effec- tive in inducing significant weight loss in patients with grade 1 obesity than only diet and exercise. Approximately 10%–15% weight loss was achieved after antral BTX-A injection in about 3 months without any significant adverse events. In that aspect, intragastric BTX-A injection could be a promising way of inducing weight loss in obese patients.
A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease
